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Abstract: We comparatively investigated the expression and clinical implications of lipid
metabolism-related proteins in invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC)
of the breast. A total of 584 breast cancers (108 ILC and 476 IDC) were subjected to tissue microarray
and immunohistochemical analysis for lipid metabolism-related proteins including hormone-sensitive
lipase (HSL), perilipin A, fatty acid binding protein (FABP)4, carnitine palmitoyltransferase (CPT)-1,
acyl-CoA oxidase 1, and fatty acid synthetase (FASN). HSL, perilipin A, and FABP4 expression (all
p < 0.001) differed significantly: HSL and FABP4 were more frequently present in ILC, whereas
perilipin A was more frequently detected in IDC. Among all invasive cancers, HSL and FABP4 were
highly expressed in luminal A-type ILC (p < 0.001) and perilipin A in luminal A-type IDC (p = 0.007).
Among luminal B-type cancers, HSL and FABP4 were more highly expressed in ILC (p < 0.001).
Univariate analysis found associations of shorter disease-free survival with CPT-1 positivity (p = 0.004)
and acyl-CoA oxidase 1 positivity (p = 0.032) and of shorter overall survival with acyl-CoA oxidase
1 positivity (p = 0.027). In conclusion, ILC and IDC exhibited different immunohistochemical lipid
metabolism-related protein expression profiles. Notably, ILC exhibited high HSL and FABP4 and low
perilipin A expression.
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1. Introduction
Invasive breast cancer, the most common type of cancer affecting women, can be roughly
subdivided into invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) [1]. ILC
comprises approximately 5%–15% of all cases of invasive carcinoma [2,3], although hormone
replacement therapy and increased alcohol consumption have led recently to a more rapid increase in
the incidence of ILC than of IDC [4,5]. Compared to IDC, ILC more frequently presents as multiple
and bilateral lesions [6,7], and is histologically characterized by non-cohesive cancer cells lacking
e-cadherin expression [8]. Furthermore, ILC commonly metastasizes to the bone, gastrointestinal tract,
uterus, meninges, and ovarian diffuse serosal surface, in contrast to the metastasis patterns exhibited
by IDC [7,9,10].
The most profound metabolic difference between tumor cells and normal cells can be summarized
as the Warburg effect, wherein tumor cells produce energy via aerobic glycolysis rather than aerobic
phosphorylation during the tricarboxylic acid cycle [11]. Although glycolysis is an important metabolic
process in the cancer cell, these cells exhibit characteristic metabolic flexibility, which may be exploitable
by cancer metabolic therapy. Metabolic reprogramming in cancer includes glucose, amino acid and
lipid metabolism (such as lipolysis, lipid transfer, and β-oxidation).
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Several enzymes function within the lipid metabolism pathway. For example, hormone-sensitive
lipase (HSL) hydrolyzes triglycerides into free fatty acids [12], whereas during lipolysis, perilipin A
acts as a lipid droplet gate-keeper [13] and fatty acid binding protein (FABP) plays key roles in lipid
transfer and functions as a free fatty acid transporter [14]. Additionally, carnitine palmitoyltransferase 1
(CPT-1) [15] and acyl-CoA oxidase 1 [16] are essential enzymes in the process of β-oxidation. Previous
comparative genomic analyses have demonstrated different mechanisms of lipid/fatty acid transport
and metabolism in ILC and IDC [17], with high expression of lipid biosynthesis genes in the former [18].
Another previous study reported the differential expression of metabolism-related proteins between
ILC and IDC [19], suggesting that these types of cancer may exhibit different patterns of lipid
metabolism-related protein expression. In the present study, therefore, we aimed to evaluate the
expression and clinical implications of lipid metabolism-related proteins in ILC.
2. Results
2.1. Basal Characteristics of ILC and IDC
The present study included 97 (89.8%) classic-type and 11 (11.1%) pleomorphic-type ILCs; the
latter were significantly associated with an older patient age (p = 0.011), higher nuclear grade (p < 0.001),
higher histologic grade (p < 0.001), higher pathologic tumor stage (p = 0.048), progesterone receptor (PR)
negativity (p = 0.018), human epidermal growth factor receptor 2 (HER-2) positivity (p = 0.002), higher
Ki-67 labeleing index (LI) (p = 0.001), and non-luminal A subtype (p < 0.001) when compared with the
former. The clinicopathologic characteristics of ILC are summarized in Table S1. Basal characteristics
of the 476 IDCs included for comparison are summarized in Table S2.
2.2. Expression of Lipid Metabolism-Related Proteins in ILC According to Histologic Type
In an evaluation according to ILC histologic type, CPT-1 and acyl-CoA oxidase 1 were more
highly expressed in pleomorphic-type tumors (p = 0.029 and p = 0.014, respectively), whereas perilipin
A expression was absent in tumor cells (Figure 1 and Table 1). Nearby normal breast tissue revealed
reduced presence or absence of lipid metabolism-related proteins compared to the tumor cells
(Figure 1).
Table 1. Expression of lipid metabolism-related proteins in ILC according to histologic type.
Parameters Total n = 108 (%) Classic Type n = 97 (%) Pleomorphic Type n = 11 (%) p-Value
HSL 0.589
Negative 8 (7.4) 7 (7.2) 1 (9.1)
Positive 100 (92.6) 90 (92.8) 10 (90.9)
Perilipin A N/A
Negative 108 (100.0) 97 (100.0) 11 (100.0)
Positive 0 (0.0) 0 (0.0) 0 (0.0)
FABP4 1.000
Negative 73 (67.6) 65 (67.0) 8 (72.7)
Positive 35 (32.4) 32 (33.0) 3 (27.3)
CPT-1 0.029
Negative 88 (81.5) 82 (84.5) 6 (54.5)
Positive 20 (18.5) 15 (15.5) 5 (45.5)
Acyl-CoA oxidase 1 0.014
Negative 97 (89.8) 90 (92.8) 7 (63.6)
Positive 11 (10.2) 7 (7.2) 4 (36.4)
FASN 0.748
Negative 72 (66.7) 64 (66.0) 8 (72.7)
Positive 36 (33.3) 33 (34.0) 3 (27.3)
N/A, not applicable; HSL, hormone-sensitive lipase; FABP4, fatty acid binding protein 4; CPT-1, carnitine
palmitoyltransferase 1; FASN, fatty acid synthetase. Significant values in bold.
Int. J. Mol. Sci. 2017, 18, 232 3 of 14
Int. J. Mol. Sci. 2017, 18, 232 3 of 13 
 
 
Figure 1. Expression of lipid metabolism-related proteins in invasive lobular carcinoma (ILC) 
according to histologic type. Higher expression levels of carnitine palmitoyltransferase 1 (CPT-1) and 
acyl-CoA oxidase 1 are observed in pleomorphic-type ILC when compared to classic-type ILC. 
Nearby normal breast tissue shows reduced presence or absence of expression of lipid 
metabolism-related proteins compared to the tumor cells. Scale bar = 100 μm. 
2.3. Comparison of the Expression of Lipid Metabolism-Related Proteins between ILC and IDC 
Differential expression of lipid metabolism-related proteins was observed in ILC and IDC 
(Table 2). HSL (p < 0.001) and FABP4 (p < 0.001) showed higher expression rates in ILC, whereas 
perilipin A (p < 0.001) was more highly expressed in IDC (Figure 2). Because most ILC cases included 
in this study were of the luminal type, we further analyzed the expression of lipid 
metabolism-related proteins in luminal-type IDCs and ILCs to determine whether the previously 
observed differential expression of lipid metabolism-related proteins was molecular 
Figure 1. Expression of lipid metabolism-related proteins in invasive lobular carcinoma (ILC) according
to histologic type. Higher expression levels of carnitine palmitoyltransferase 1 (CPT-1) and acyl-CoA
oxidase 1 are observed in pleomorphic-type ILC when compared to classic-type ILC. Nearby normal
breast tissue shows reduced presence or absence of expression of lipid metabolism-related proteins
compared to the tumor cells. Scale bar = 100 µm.
2.3. Comparison of the Expression of Lipid Metabolism-Related Proteins between ILC and IDC
Differential expression of lipid metabolism-related proteins was observed in ILC and IDC (Table 2).
HSL (p < 0.001) and FABP4 (p < 0.001) showed higher expression rates in ILC, whereas perilipin A
(p < 0.001) was more highly expressed in IDC (Figure 2). Because most ILC cases included in this study
were of the luminal type, we further analyzed the expression of lipid metabolism-related proteins in
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luminal-type IDCs and ILCs to determine whether the previously observed differential expression
of lipid metabolism-related proteins was molecular subtype-dependent (Table 3). Among luminal
A-type tumors, ILC exhibited higher expression of HSL (p < 0.001) and FABP4 (p < 0.001), whereas
IDC exhibited higher expression of perilipin A (p = 0.007). Similarly, ILC luminal B-type tumors more
highly expressed HSL (p < 0.001) and FABP4 (p < 0.001), compared with IDC.
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Table 2. Expression of lipid metabolism-related proteins in ILC and IDC.
Parameters Total n = 584 (%) ILC n = 108 (%) IDC n = 476 (%) p-Value
HSL <0.001
Negative 414 (70.9) 8 (7.4) 406 (85.3)
Positive 170 (29.1) 100 (92.6) 70 (14.7)
Perilipin A <0.001
Negative 530 (90.8) 108 (100.0) 422 (88.7)
Positive 54 (9.2) 0 (0.0) 54 (11.3)
FABP4 <0.001
Negative 541 (92.6) 73 (67.6) 468 (98.3)
Positive 43 (7.4) 35 (32.4) 8 (1.7)
CPT-1 0.322
Negative 494 (84.6) 88 (81.5) 406 (85.3)
Positive 90 (15.4) 20 (18.5) 70 (14.7)
Acyl-CoA oxidase 1 0.561
Negative 515 (88.2) 97 (89.8) 418 (87.8)
Positive 69 (11.8) 11 (10.2) 58 (12.2)
FASN 0.825
Negative 384 (65.8) 72 (66.7) 312 (65.5)
Positive 200 (34.2) 36 (33.3) 164 (34.5)
ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; HSL, hormone-sensitive lipase; FABP4, fatty acid
binding protein 4; CPT-1, carnitine palmitoyltransferase 1; FASN, fatty acid synthetase. Significant values in bold.
Table 3. Comparison of lipid metabolism-related protein expression in luminal-type ILC and IDC.
Parameters
Luminal A Type Luminal B Type
ILC n = 82 (%) IDC n = 242 (%) p-Value ILC n = 21 (%) IDC n = 134 (%) p-Value
HSL <0.001 <0.001
Negative 5 (6.1) 199 (82.2) 3 (14.3) 115 (85.8)
Positive 77 (93.9) 43 (17.8) 18 (85.7) 19 (14.2)
Perilipin A 0.007 0.120
Negative 82 (100.0) 222 (91.7) 21 (100.0) 120 (89.6)
Positive 0 (0.0) 20 (8.3) 0 (0.0) 14 (10.4)
FABP4 <0.001 <0.001
Negative 57 (69.5) 240 (99.2) 14 (66.7) 133 (99.3)
Positive 25 (30.5) 2 (0.8) 7 (33.3) 1 (0.7)
CPT-1 0.442 0.175
Negative 71 (86.6) 217 (89.7) 14 (66.7) 107 (79.9)
Positive 11 (13.4) 25 (10.3) 7 (33.3) 27 (20.1)
Acyl-CoA oxidase 1 0.515 0.521
Negative 78 (95.1) 234 (96.7) 18 (85.7) 121 (90.3)
Positive 4 (4.9) 8 (3.3) 3 (14.3) 13 (9.7)
FASN 0.657 0.340
Negative 52 (63.4) 160 (66.1) 16 (76.2) 88 (65.7)
Positive 30 (36.6) 82 (33.9) 5 (23.8) 46 (34.3)
ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; HSL, hormone-sensitive lipase; FABP4, fatty acid
binding protein 4; CPT-1, carnitine palmitoyltransferase 1; FASN, fatty acid synthetase. Significant values in bold.
2.4. Correlation between Lipid Metabolism Proteins and Clinicopathologic Factors in ILC
In ILC, acyl-CoA oxidase 1 expression was associated with estrogen receptor (ER) negativity
(p < 0.001), PR negativity (p = 0.007), a higher nuclear grade (p = 0.002), and higher histologic grade
(p = 0.007) (Figure 3).
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Figure 3. Correlation between the expression of lipid metabolism-related proteins and clinicopathologic
factors in invasive lobular carcinoma. In ILC, acyl-CoA oxidase 1 expression is associated with ER
negativity (p < 0.001), PR negativity (p = 0.007), higher nuclear grade (p = 0.002), and higher histologic
grade (p = 0.007).
2.5. Impact of Lipid Metabolism-Related Protein Expression on Prognosis in ILC
In a univariate analysis of ILC, CPT-1 positivity (p = 0.004) and acyl-CoA oxidase 1 positivity
(p = 0.032) were associated with a shorter disease-free survival (DFS; Table 4 and Figure 4); however,
no significantly predictive protein expression status was identified in a multivariate analysis (Table S3).
In a univariate analysis of all invasive breast cancers (n = 584), a shorter DFS was associated with HSL
negativity (p = 0.024) and acyl-CoA oxidase 1 positivity (p = 0.028), whereas a shorter overall survival
(OS) was associated only with acyl-CoA oxidase 1 positivity (p = 0.027) (Table 5). In a prognostic
analysis of all invasive breast cancers according to molecular subtype, FABP4 positivity (p = 0.023) and
CPT-1 positivity (p = 0.027) were associated with a shorter DFS among triple negative breast cancers
(TNBCs) (Figure 4).
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Table 4. Univariate analysis (log-rank test) of the impacts of lipid metabolism-related protein expression
in invasive lobular carcinoma on disease-free and overall survival.
Parameters
Disease-Free Survival Overall Survival
95% CI p-Value 95% CI p-Value
HSL 0.286 N/A
Negative 104 (104–104) N/A
Positive 187 (167–201) N/A
FABP4 0.573 0.326
Negative 177 (154–200) 183 (165–200)
Positive 111 (104–118) 110 (100–120)
CPT-1 0.004 N/A
Negative 186 (168–203) N/A
Positive 98 (87–108) N/A
Acyl-CoA oxidase 1 0.032 0.759
Negative 185 (165–204) 181 (162–199)
Positive 103 (90–115) 117 (104–130)
FASN 0.150 0.787
Negative 184 (165–204) 178 (158–197)
Positive 103 (96–110) 122 (116–127)
CI, confidence interval; HSL, hormone-sensitive lipase; N/A, not applicable; FABP4, fatty acid binding protein 4;
CPT-1, carnitine palmitoyltransferase 1; FASN, fatty acid synthetase. Significant values in bold.Int. J. Mol. Sci. 2017, 18, 232 7 of 13 
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Table 5. Univariate analysis (log-rank test) of the impacts of lipid metabolism-related protein expression
in invasive breast cancers on disease-free and overall survival.
Parameters
Disease-Free Survival Overall Survival
95% CI p-Value 95% CI p-Value
HSL 0.024 0.154
Negative 99 (97–101) 104 (102–106)
Positive 185 (168–201) 178 (160–195)
Perillipin A 0.977 0.795
Negative 173 (153–193) 176 (161–190)
Positive 81 (78-84) 81 (78–84)
FABP4 0.895 0.607
Negative 172 (150–193) 177 (161–193)
Positive 109 (101–116) 108 (97–119)
CPT-1 0.183 0.194
Negative 180 (163–197) 175 (159–192)
Positive 97 (93–101) 117 (111–122)
Acyl-CoA oxidase 1 0.028 0.027
Negative 180 (161–198) 177 (160–195)
Positive 100 (90–111) 108 (94–122)
FASN 0.313 0.112
Negative 177 (159–196) 171 (153–189)
Positive 104 (98–109) 121 (119–124)
CI, confidence interval; HSL, hormone-sensitive lipase; FABP4, fatty acid binding protein 4; CPT-1, carnitine
palmitoyltransferase 1; FASN, fatty acid synthetase. Significant values in bold.
3. Discussion
This investigation of lipid metabolism-related protein expression in ILC and IDC revealed
characteristic patterns involving higher expression of HSL and FABP4 in ILC and perilipin A in IDC.
A previous hierarchical clustering study showed four distinct groups of breast cancer, based on the gene
expression level [17]. In that study, group IV, which was predominantly comprised of ILC, exhibited
very high levels of adipose tissue marker expression relative to the other groups [17]. In addition, ILCs
classified into group II also exhibited high levels of adipose tissue marker expression [17], findings
consistent with the results of present study. That study also found high expression of the adipose
tissue markers FABP4 and lipase in ILC [17], as demonstrated in the present study. Our study and
the previous study differ, however, with regard to perilipin expression; the previous study reported
upregulation of this protein in ILC [17], whereas our study failed to detect this protein in ILC tumor
cells. We attribute this discrepancy to the evaluation of different cell compartments. The previous study
used whole-tissue profiling, in which average gene expression level from all cells in a tumor sample is
evaluated regardless of cell type. Meanwhile, we used immunohistochemistry to discriminate specific
expression sites (e.g., tumor or stromal cells) of each molecule. Using this method, we observed
perilipin A expression in adipocytes within the tumor stroma of ILC, and note that further study
is needed to identify the cellular origin of this expression. We further confirmed the differential
expression of lipid metabolism-related proteins in ILC and IDC samples was restricted to luminal-type
tumors, suggesting that the observed differences in lipid metabolism-related protein expression are
independent of molecular subtype. This finding was also observed by Weigelt et al., who found that
the different transcriptomes of ILC and IDC were retained even after molecular subtype matching [18].
In the present study, we observed different levels of lipid metabolism-related protein expression
between the two ILC subtypes; specifically, pleomorphic-type tumors showed higher expression of
CPT-1 and acyl-CoA oxidase 1. The pleomorphic-type ILC is an aggressive variant known to harbor
more adverse biomarker profiles such as hormone receptor negativity, HER-2 positivity, and a high
Ki-67 LI when compared with classic-type ILC [20,21]. Despite differences in tumor biology, however,
molecular studies have revealed a common molecular genetic pathway shared by pleomorphic- and
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classic-type tumors [22–24]. A previous finding of higher perilipin expression in classic-type ILC vs.
ductal-like ILC [17] suggested the potential for differential expression of adipocyte-related molecules in
ILC subgroups. Aberrant CPT-1 expression has been found to be associate with high-grade glioma [25],
suggesting a correlation between lipid metabolism-related protein expression and a higher tumor
grade. In ILC, CPT-1 positivity and acyl-CoA oxidase 1 positivity were found to correlate with poor
prognosis. This finding was concordant with previous studies that observed associations between poor
prognosis and CPT-1 expression in esophageal cancer [26] or acyl-CoA oxidase 1 positivity in breast
cancer [27]. We also found the association between expression of lipid metabolism-related proteins
and poor prognosis in the breast cancer subtypes: HSL negativity and acyl-CoA oxidase 1 positivity in
invasive breast cancer, and FABP4 positivity and CPT-1 positivity in the TNBC subgroup. Thus, lipid
metabolism-related proteins appear to be a potential prognostic factor in variable subgroups of breast
cancer, reflecting tumor aggressiveness.
In addition to the upregulated adipose markers in ILC [17], the inhibition of FABP-4 [28] and
CPT-1 [29,30], which were found to be highly expressed in ILC and pleomorphic-type ILC, respectively,
have been reported to block tumor growth, indicating that lipid metabolism could be targeted in
the context of ILC treatment. Increase of fat oxidation and subsequent lipolysis are observed under
exercise of low to moderate intensity, resulted by increased fatty acid availability. However, lipolysis
is reduced at high exercise intensity due to increase of carbohydrate oxidation from glycolytic flux
and reduced CPT-1 activity [31]. This phenomenon has clinical relevance that could reduce the insulin
resistance and metabolic disease, which can increase risk of cancer development, including breast
cancer [32]. As described in present study, CPT-1 is a potential therapeutic target in ILC, particularly
in the pleomorphic subtype, and indirect reduction of CPT-1 activity via intense exercise may have
a therapeutic effect in ILC patients. Since obesity is one risk factor associated with poor outcome of
breast cancer patients [33], exercise could improve indirectly also the prognosis in women with breast
cancer [32,34].
One of major limitation of present study was an unbalanced patient number among the subgroups.
There were relatively small numbers of ILC patients when compared to IDC, and even fewer numbers
of pleomorphic-type ILC patients in comparison to classic-type ILC, which might be inappropriate
for statistical analysis, and could lead to skewed results. However, this imbalance is derived from its
small intrinsic prevalence of ILC and pleomorphic-type ILC. In prior studies, when comparing IDC
and ILC, ILC represented approximately 10% in proportion [35–37]. Furthermore, pleomorphic-type
ILC accounts for 13% of ILC cases; this proportion could be even smaller in the overall invasive breast
cancer category [38].
In conclusion, we observed different expression profiles of lipid metabolism-related proteins in
ILC when compared with IDC. ILC showed higher expression of HSL and FABP4 and lower expression
of perilipin A. In addition, CPT-1 and acyl-CoA oxidase 1 expression were found to be associated with
a shorter DFS in ILC. Discovery of the differential expression lipid metabolism-related proteins in ILC
has clinical implications, as it could provide potential therapeutic targets.
4. Materials and Methods
4.1. Patient Selection and Clinicopathologic Evaluation
This study was approved by the Institutional Review Board (IRB) of Severance Hospital (IRB No.
4-2014-0701, October 2014). The informed consent form patient was waivered by the IRB. The study
was conducted in accordance with the Declaration of Helsinki. From January 2000 to December 2012;
a total of 108 patients who were diagnosed with ILC and underwent surgical resection at Severance
Hospital were selected. An additional 476 patients with IDC of no specific type were included for
comparison. Patients who had received neoadjuvant chemotherapy were excluded.
Int. J. Mol. Sci. 2017, 18, 232 10 of 14
For the histologic analysis, all hematoxylin and eosin (H&E)-stained slides were retrospectively
reviewed by a breast pathologist (Koo, J.S.), who assessed the histological grade according to the
Nottingham grading system [39]. Tumor staging was based on the seventh American Joint Committee
on Cancer (AJCC) criteria. Disease-free survival (DFS) was calculated from the date of the first curative
surgery to the date of the first loco-regional or systemic relapse, or death without any type of relapse.
Overall survival (OS) was estimated from the date of the first curative operation to the date of the
last follow-up or death from any cause. The clinicopathologic parameters evaluated for each breast
cancer included the patient’s age at initial diagnosis, lymph node metastasis, tumor recurrence, distant
metastasis, and survival status.
4.2. Tissue Microarray
After a review of H&E-stained slides, matched formalin-fixed paraffin-embedded (FFPE) tumor
tissue samples were retrieved for the most appropriate sections. Subsequently, tissue microarrays were
constructed using two 3-mm tissue cores punched from each retrieved FFPE tumor tissue. The most
representative tumor areas were selected from each tumor.
4.3. Immunohistochemistry
Antibodies used for immunohistochemistry in this study are shown in Table 6.
Immunohistochemical staining was applied to FFPE tissue sections. Briefly, 3-mm paraffin sections
were deparaffinized and rehydrated in solutions of xylene and alcohol. Immunohistochemistry was
performed using a Ventana Discovery XT automated stainer (Ventana Medical Systems, Tucson, AZ,
USA), following antigen retrieval with Cell Conditioning 1 (CC1; citrate buffer pH 6.0, Ventana Medical
System). Appropriate positive and negative controls for immunohistochemistry were included.
Table 6. Source, clones, and dilutions of antibodies used in this study.
Antibody Company Clone Dilution
Lipolysis-related
HSL Abcam, Cambridge, UK Polyclonal 1:100
Perilipin A Abcam, Cambridge, UK Polyclonal 1:100
FABP4 Abcam, Cambridge, UK Polyclonal 1:100
CPT-1 Abcam, Cambridge, UK 8F6AE9 1:200
Acyl-CoA oxidase 1 Abcam, Cambridge, UK Polyclonal 1:50
FASN Abcam, Cambridge, UK Polyclonal 1:100
Molecular subtype related proteins
ER Thermo Scientific, San Siego, CA, USA SP1 1:100
PR DAKO, Glostrup, Denmark PgR 1:50
HER-2 DAKO, Glostrup, Denmark Polyclonal 1:1500
Ki-67 Abcam, Cambridge, UK MIB 1:1000
HSL, hormone-sensitive lipase; FABP4, fatty acid binding protein 4; CPT-1, carnitine palmitoyltransferase-1; FASN,
fatty acid synthetase; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor
receptor 2.
4.4. Interpretation of Immunohistochemical Results
A cut-off value of ≥1% positively-stained nuclei was used to define estrogen receptor (ER) and
progesterone receptor (PR) positivity [40]. Human epidermal growth factor receptor 2 (HER-2) staining
was analyzed according to the American Society of Clinical Oncology (ASCO)/College of American
Pathologists (CAP) guidelines, using the following categories: 0 = no immunostaining; 1+ = weak
incomplete membranous staining, <10% of tumor cells; 2+ = complete membranous staining, either
uniform or weak in ≥ 10% of tumor cells; and 3+ = uniform intense membranous staining in ≥30% of
tumor cells [41]. HER-2 expression was considered positive when strong (3+) membranous staining
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was observed, whereas cases with scores of 0 to 1+ were considered negative. Cases exhibiting
equivocal (2+) HER-2 expression were subjected to further evaluation of HER-2 gene amplification
using fluorescent in situ hybridization (FISH).
The results of immunohistochemical staining for lipid metabolism-related proteins were scored
by multiplying scores indicating the proportion of stained cells (negative, 0; <30% positive, 1; ≥30%
positive, 2) by scores indicating the immunostaining intensity (negative, 0; weak, 1; moderate, 2;
strong, 3). Scores of 0–1 were interpreted as negative; scores of 2–6 were considered positive [42].
4.5. Tumor Phenotype Classification
In this study, we classified breast cancer phenotypes according to ER, PR, and HER-2
immunohistochemistry results and Ki-67 labeling index (LI). HER-2 FISH results were used to
categorize tumors as follows [43]: luminal A type: ER and/or PR positive, HER-2 negative, and
Ki-67 LI < 14%; luminal B type: (HER-2 negative) ER and/or PR positive, HER-2 negative, and Ki-67
LI ≥ 14% and (HER-2 positive) ER and/or PR positive and HER-2 overexpressed and/or amplified;
HER-2 type: ER and PR negative and HER-2 overexpressed and/or amplified; TNBC (triple-negative
breast cancer) type: ER, PR, and HER-2 negative.
4.6. Statistical Analysis
Data were statistically processed using SPSS for Windows, version 20.0 (SPSS Inc., Chicago, IL,
USA). Student’s t-test and Fisher’s exact test were used to assess continuous and categorical variables,
respectively. Statistical significance was assumed at a p-value < 0.05. Kaplan–Meier survival curves
and log-rank statistics were employed to evaluate the time interval to tumor metastasis and survival
duration. A Cox proportional hazards model was used to assess the risk factors of shorter DFS and OS.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/1/232/s1.
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